Die Differentialtherapie des Typ-II-Diabetes

  • P.-H. Althoff
  • C. Rosak
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 92)

Zusammenfassung

Im Gegensatz zum Insulin-abhängigen Typ-I-Diabetes ist der primär nicht Insulin-abhängige Typ-II-Diabetes bezüglich des Ausmaßes der gestörten β-Zellfunktion sowie der Insulin Wirkung am Rezeptor, bzw. des Postrezeptordefektes heterogener und inhomogener als angenommen [108].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Althoff P-H, Faßbinder W, Neubauer M, Koch KM, Schöfflin K (1978) Hämodialyse bei der Behandlung der Biguanid-induzierten Lactatazidose. Dtsch Med Wschr 103:61PubMedGoogle Scholar
  2. 2.
    Althoff P-H, Haupt E, Schöfflin K (1985) Prädiktoren des Sulfonylharnstoffversagens, 5. Bad Neuenahrer Diabetes-Tagung 1985. In: Drost H, Gries FA, Jahnke K (eds) Der nicht-insulinabhängige Diabetes mellitus (Typ II). Schattauer, Stuttgart New YorkGoogle Scholar
  3. 3.
    Asplund K, Wiholm BE, Lithner F (1983) Glibenclamid-associated hypoglycaemia: A report on 57 cases. Diabetologia 24:412–417PubMedGoogle Scholar
  4. 4.
    Bachmann W, Sieger C, Lotz N (1983) Kombinationstherapie Insulin/Glibenclamid bei Typ-II-Diabetikern mit relativer Insulinresistenz. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 145Google Scholar
  5. 5.
    Bachmann W (1982) Insulin plus Sulfonylharnstoff-eine (un)mögliche Kombination? Dtsch Med Wschr 5:163Google Scholar
  6. 6.
    Bachmann W, Lotz N, Mehnert H (1984) Kombinationstherapie Insulin/Sulfonylharnstoff (KOMB) bei Typ-II-Diabetikern mit Sekundärversagen einer Sulfonylharnstofftherapie. Akt Endokr 5:78Google Scholar
  7. 7.
    Bachmann W, Mehnert H (Hrsg) (1983) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, BaselGoogle Scholar
  8. 8.
    Beck-Nielson H, Pedersen O, Lindskov HO (1979) Increased insulin sensitivity and cellular insulin binding to obese diabetics following treatment with glibenclamid. Acta endocr (Kbh.) 90:451Google Scholar
  9. 9.
    Beck-Nielson H, Hjollund O, Pedersen HO, Richelsen B, Schwartz-Sorensen N (1984) Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Diabetes Care, Vol 7 (Suppl 1): 100–105Google Scholar
  10. 10.
    Beckmann R: Pharmakologie und Wirkungsmechanismus der Biguanide beim Tier. In: Oberdisse K (Hrsg) Diabetes mellitus, 5. Aufl., Bd 7, Teil 2B. Springer, Berlin Heidelberg New York, S 951Google Scholar
  11. 11.
    Beischer W, Keller L, Maas M, Schiefer E, Pfeiffer F (1976) Human C-Peptide. Part I Radioimmunoassay. Klin Wschr 54:709PubMedGoogle Scholar
  12. 12.
    Beischer W, Schmid M, Kerner W, Keller L, Pfeiffer EF (1979) Feedback inhibition of insulin in healthy and overweight subjects studied by use of an artificial endocrine pancreas. Horm Metab Res (Suppl. Series) 8:97Google Scholar
  13. 13.
    Berger M, Standi E (1981) Sulfonylharnstoff in der Diabetestherapie 1981. DMW 106:1443–1446Google Scholar
  14. 14.
    Berger W (1979) Present status of biguanides. Pharma-Kritik 1:9Google Scholar
  15. 15.
    Bieger WP, Dlugosch R, Retenmeier A, Holler HD, Bert H, Schwarz W, Fiehn W(1984) Trial of Sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Klin Wschr 62:13:631Google Scholar
  16. 16.
    Björntorp P, Krotkiewski M (1985) Exercise treatment in diabetes mellitus (Review). Acta Med Scand 217:3–7PubMedGoogle Scholar
  17. 17.
    Bolinder J, Östman J, Arner P (1985) Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetes by treatment with diet and sulfonylurea. Acta endocr 108:85–90PubMedGoogle Scholar
  18. 18.
    Burke BJ, Sheriff J (1980) Stimulation insulin secretion by glibenclamid in insulin dependent diabetics. Acta endocr (Kbh) 98:372Google Scholar
  19. 19.
    Burke BJ, Hartog M, Waterfield MR (1984) Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide. Acta Endocr 107:70–77PubMedGoogle Scholar
  20. 20.
    Campbell IW (1984) Metformin and gloibeclamide: comparative risks. Brit med J 289:289Google Scholar
  21. 21.
    Caspary WF (1985) Diabetes mellitus: Verzögerung der Kohlenhydrat-Resorption als therapeutisches Prinzip. Dtsch Ärzteblatt 82:1413–1423Google Scholar
  22. 22.
    Caspary, WF: Sucrose-malabsorption in man after ingestion of a-Glucoide-hydrolase inhibitorGoogle Scholar
  23. 23.
    Cohen D, Prezzing V, Vigneri R, Avola R, D’Agatha R, Polosa P (1980) Phenformin increase insulin binding to human cultured breast cancer cells. Diabetes 29:329PubMedGoogle Scholar
  24. 24.
    Creuzfeld W (Hrsg) (1982) First International Symposium on Acarbos. Effects on carbohydrate and Fat Metabolism. Exerpta Medica, AmsterdamGoogle Scholar
  25. 25.
    Davidson JK Newer approaches to diet management of diabetes: caloric control. Med Times 108:35Google Scholar
  26. 26.
    Daweke H, Braun F, Bach J, Schäfer D (1983) Freisetzung endogener Insulinreserven bei kombinierter Insulin/Sulfonylharnstoff-Therapie von Typ-II-Diabetikern. Akt Endokr 4:177Google Scholar
  27. 27.
    De Fronzu R, Simonson DC (1984) Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care, Vol. 7 (Suppl 1):72–80Google Scholar
  28. 28.
    De Fronzo RA, Simonson D, Ferrannini E (1982) Hepatic and peripheral insulin resistance: A common feature of type II (non-insulin-dependent) and type I (insulin-dependent) diabetes mellitus. Diabetologia 23:313–319Google Scholar
  29. 29.
    De Fronzo RA, Ferrannini E (1982) The pathogenesis of non-insulin dependent diabetes. Medicine 61:125–140Google Scholar
  30. 30.
    De Lawtwe DE, Moss JM, Tyroler S et al. (1960) Secondary failure of response to tolbutamine treatment. JAMA 171:731Google Scholar
  31. 31.
    Deutsche Diabetes-Gesellschaft (1983) Orale Diabetes-Therapie mit Medikamenten vom Typ der Sulfonylharnstoffe. Stellungnahme. Diabetologie-Informationen, Heft 2:27Google Scholar
  32. 32.
    Doar JWH, Thomson ME, Wilde CE, Sewell PFJ (1975) Influence of treatment with diet alone on oral glucose tolerance test and plasma sugar and insulin levels in patients with matuity-onset diabetes mellitus. Lancet 1:1263–1266PubMedGoogle Scholar
  33. 33.
    Emanuele NV, Lawrence AM (1985) Management of type II diabetes mellitus Postgraduate Med 77:61–71Google Scholar
  34. 34.
    Fabrykant M (1958) Use of orinase as a basic adjuvant management of insulin-dependent diabetes. etabolism 7:213Google Scholar
  35. 35.
    Felber JP, Meyer HU, Curchod B, Maeder E, Pahud E, Jequier E (1981) Effect of 3-day fast on glucose storage and oxidation in obese hyperinsulinemic diabetics. Metabolism 30:184–189PubMedGoogle Scholar
  36. 36.
    Feldmann JM, Lebovitz HE (1971) Endocrine and metabolic effects of glybenclamide. Evidence for an extrapancreatic mechanism of action. Diabetes 20:745Google Scholar
  37. 37.
    Ferner RE, Alberti KGM (1986) Why is there still disagreement over insulin secretion in noninsulin-dependent diabetes. Diabetic Med, Vol 3:13–17PubMedGoogle Scholar
  38. 38.
    Gamba S, Campana M, Carlini M, Grassi G, Regis G, Bruni B (1982) Residual insulin secretion in diabetic patients treated firstly with sulphonylureas and then with insulin. Diabetologia 23:168Google Scholar
  39. Gerö L, Koranyi L, Tamas Gy Jr (1982) Remission-like improvement in residual B-cell function of insulin treated type-II (non-insulin dependent) diabetics following the introduction of insulin therapy. Diabetologia 23:169Google Scholar
  40. 40.
    Gries FA, Toeller M (1977) Grundlagen der Diabetesdiät. Aktuel Ernähr 2:120Google Scholar
  41. 41.
    Groop L, Harno K, Tappanen E-M. (1984) The combination of insulin and sulfonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta endocrinologica 106:1–97Google Scholar
  42. 42.
    Groop L, Pelkonen R, Koskimies S (1982) The mechanisms of secondary drug failure in patients with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 23:171Google Scholar
  43. 43.
    Hadden DR, Montgomery DAD, Skelly RJ, Trible ER, Weaver JAS, Wilson EA, Buchanan KD (1975) Maturity-onset diabetes mellitus: response to intensive dietary management. Brit Med J 3:276–278PubMedGoogle Scholar
  44. 44.
    Hamelbeck H, Klein W, Zoltobrocki M, Schöffling K (1982) Glibenclamid/Insulin-Kombinationsbehandlung beim Sekundärversagen der Sulfonylharnstoff-Therapie. Dtsch Med Wschr 107Google Scholar
  45. 45.
    Haupt E (1983) Über die Grenzen der Anwendbarkeit und den Verlust der Wirksamkeit von blutzuckersenkenden Sulfonamiden in der Dauertherapie. 18. Jahres-Tg. d. Dtsch. Diabetes-Gesellschaft, Göttingen, 12.-14. Mai 1983Google Scholar
  46. 46.
    Haupt E, Laube F, Loy H, Schöffling K (1977) Neue Untersuchungen zum Sekundärversagen der Therapie mit Blutglukosesenkenden Sulfonamidderivaten. Med Klinik 72:1529Google Scholar
  47. 47.
    Henrichs HR (1983) Kombinierte Sulfonylharnstoff/Insulin-Therapie bei Diabetes mellitus nach Tabletten-sekundärversagen -praktisches klinisches Vorgehen. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 106Google Scholar
  48. 48.
    Henrichs HR, Bleicher-Ewe G, Marschall M, Schwarze B (1985) SH-Insulin-Kombination (SH-I) bei Diabetes mellitus nach Tablettensekundärversagen (TV) Ergebnisse einer Doppelblind-Glibenclamid-Cross over-Auslaßstudie. Act Endokr 6:88Google Scholar
  49. 49.
    Holman RR, Turner RC (1977) Diabetes, the quest for basal normoglycemia. Lancet 1:469–474PubMedGoogle Scholar
  50. 50.
    Holman RR, Turner RC (1979) Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes. Diabetes 28:227–230PubMedGoogle Scholar
  51. 51.
    Holman RR, Turner RC (1980) The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocr 14:279–286Google Scholar
  52. 52.
    Howe-Davies S, Simpson RW, Turner RC (1980) Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care, Vol 3, No. 5:607–610PubMedGoogle Scholar
  53. 53.
    Jahnke K (1981) Behandlung des Erwachsenen-Diabetes (Typ-II). Verh Dtsch Ges Inn Med 87:25–34PubMedGoogle Scholar
  54. 54.
    Jahnke K, Jahnke KA, Reis HE (1976) Über die Regenerationsfáhigkeit der ß-Zellfunktion bei adipösen Diabetikern nach Gewichtsreduktion. Dtsch Med Wschr 101:73PubMedGoogle Scholar
  55. 55.
    Jahnke KA, Reis HE, Jahnke K (1976) Beurteilung der ß-Zellenfunktion des Diabetikers durch Bestimmung der endogenen Insulinsekretion nach Glukose-Tolbutamidstimulation. Med Welt (NF) 27:2293Google Scholar
  56. 56.
    Jarett RJ, Keen H (1976) Hyperglycemia and diabetes mellitus. Lancet II: 1009Google Scholar
  57. 57.
    Jenkins DJA, Wolever TMS, Tailor RH et al. (1981) Glycemic index of foods: a physiological basis for carbohydrate exchanges. Am J Clin Nutr 34:362PubMedGoogle Scholar
  58. 58.
    Jenkins DJA, Wolever TMS, Nineham R, Sarson DL, Bloom SR, Ahern J, Alberti KGMM, Hockaday TDR (1980) Improved glucose tolerance four hours after taking guar with glucose. Diabetologia 19:21PubMedGoogle Scholar
  59. 59.
    Katzeff HL, Savage PJ, Barclay-White B, Nagulesparan M, Bennett PH (1985) C-Peptide measurement in the differentiation of type I and type II diabetes mellitus. Diabetologia 28:264–268PubMedGoogle Scholar
  60. 60.
    Klein W (1983) Die Kombination Insulin/Glibenclamid bei Sekundärversagen der Sulfonylharnstofftherapie. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 117Google Scholar
  61. 61.
    Klujko J, Reiter J, Beischer W, Hrstka V, Schmidt FH (1984) Untersuchungen zum Wirkungsmechanismus der kombinierten Gabe von Glibenclamid und Insulin bei Typ-II-Diabetikern. Akt Endokr 5:97Google Scholar
  62. 62.
    Koller S, Pichl J, Volkholz HJ, Sailer D (1984) Kombinierte Insulin/Glibenclamid-Therapie bei Typ-II-Diabetes. Akt Endokr 5:97Google Scholar
  63. 63.
    Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olevsky JM (1984) The acute and chronic effects of sulfonylurea-therapy in type II diabetes subjects. Diabetes, Vol 33:346–354PubMedGoogle Scholar
  64. 64.
    Kolterman O, Olevsky JM (1984) The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care, Vol 7 (Suppl 1): 81–88PubMedGoogle Scholar
  65. 65.
    Kolterman OG, Griffin J, Olevsky JM (1982) Response to Glybenclamide is restored in confirmed secondary failure patients following 14 days of exogenous insulin therapy. Clin Res 30:397 AGoogle Scholar
  66. 66.
    Krall LP, Bradley RF (1962) “Secondary failures” in the treatment of the diabetes mellitus with tolbutamide and with phenformin. Diabetes 11 (Suppl):88Google Scholar
  67. 67.
    Krall LP, Chabot VA (1978) Oral Hypoglycemic agents update. Med Clin North Am 62:681PubMedGoogle Scholar
  68. 68.
    Kromann H, Borch E, Gale EAM (1981) Unnecessary insulin treatment for diabetes. Brit Med J 283:386–388Google Scholar
  69. 69.
    Kunkel W, Haupt E, Fröhlich A, Schöffling K (1972) Der Einfluß einer Gewichtsreduktion auf Verlauf und Behandlung des Erwachsenendiabetes. Erfahrungen an 228 Patienten. Med Welt 23:679PubMedGoogle Scholar
  70. 70.
    Kyllästinen M, Groop L (1982) Glibenclamide improves the glycaemic control in insulin-treated elderly diabetic patients. European Association for the Study of Diabetes. 18th Annual Meeting, Budapest, Abstract No. 182Google Scholar
  71. 71.
    Lahtela J, Arranta J, Sotaniemi EA (1985) Enzyme inducers improve insulin sensivity in non-insulin-dependent diabetic subjects. Diabetes 34:911–916PubMedGoogle Scholar
  72. 72.
    Laube H (1983) Die Stellung von Enzyminhibitoren in der Diabetestherapie. Internistische Welt 1Google Scholar
  73. 73.
    Lipson LG, Lipson M (1984) The therapeutic approach to the obese maturity-onset diabetic patients. Arch ntern Med 114:135–138Google Scholar
  74. 74.
    Lotz N, Bachmann W, Mehnert H (1985) Vorzüge der Kombinationstherapie von Sulfonylharnstoff (SH) mit Insulin bei Typ-II-Diabetes mit „Sekundärversagen einer SH-Therapie“ (SSH). Akt Endokr 6:98Google Scholar
  75. 75.
    Lotz N, Sieger C, Bachmann W (1983) Kombinationstherapie von Glibenclamid plus Insulin bei Typ-II-Diabetes mit „Sekundärversagen“ einer Sulfonylharnstofftherapie. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 124Google Scholar
  76. 76.
    Lyons TJ, Kennedy L, Atkinson AB, Buchanan KD, Hadden DR, Weaver JA (1984) Predicting the need for Insulin Therapy in late onset (40–69 years) Diabetes mellitus. Nothern Ireland: 105–107Google Scholar
  77. 77.
    Mehnert H, Reisner E (1964) Untersuchungen zur Frage des sog. Spätversagens der Sulfonylharnstofftherapie. Dtsch Med Wschr 89:1378PubMedGoogle Scholar
  78. 78.
    Mehnert H (1962) Clinical and experimental findings after five years treatment of diabetes with sulfonylureas. Diabetes 11 (Suppl): 80PubMedGoogle Scholar
  79. 79.
    Muir A, Howe-Davies SA, Turner RC (1982) General practice care of non-insulin-dependent diabetes with fasting blood glucose measurements. Am J Med 73:637–640PubMedGoogle Scholar
  80. 80.
    Nankervis J, Proitto J, Aitken P, Harewood M, Afford F (1982) Differential effects of insulin therapy on hepatic and peripheral Insulin sensitivity in type II (non-insulin-dependent) diabetes. Diabetologia 23:320–325PubMedGoogle Scholar
  81. 81.
    National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039Google Scholar
  82. 82.
    Nicholas VE, Lawrence AM (1985) Management of type II diabetes mellitus. Achieving optimum metabolic control. Postgrad Med 77 8:61–71Google Scholar
  83. 83.
    Olevsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leucocytes of diabetic patients. Am J Med 60:89Google Scholar
  84. 84.
    Olevsky JM, Koltermann OG (1981) Mechanisms of insulin resistance in obesity and non-insulin-dependent (type II) diabetes. Am J Med Vol 70:151–168Google Scholar
  85. 85.
    Otto H (1985) Therapie des Diabetes mellitus: Einstellungskriterien und Erfolgskontrolle (Richtlinien d. Dtsch. Diabetes-Gesellschaft). Akt Endokrin u. Stoffw 6:148–149Google Scholar
  86. 86.
    Owens DR, Biggs PI, Shetty KJ, Wragg KG (1980) The effect of glibenclamid on the glucose and insulin profile in maturity onset diabetes following both acute and long term treatment. Diabete and Metabolisme 6:219–224PubMedGoogle Scholar
  87. 87.
    Owens DR, Wragg KG, Schetty KT, Biggs PI, Davies CD (1979) Glibenclamide. Acute long-term response imn M.O. diabetes. Horm Metab Res 11:411PubMedGoogle Scholar
  88. 88.
    Peacock I, Tattersall RB (1984) The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Brit Med J 288:1956–1959Google Scholar
  89. 89.
    Pfeiffer MA, Halter JB, Porte DP (1981) Insulin secretion in diabetes mellitus. Am J Med Vol 70Google Scholar
  90. 90.
    Pfeiffer MA, Halter JB, Judzewitsch RG, Porte D (1984) Acute and chronic effects of sulfonylurea drugs on pancreatic islets function in man. Diabetes Care, Vol 7 (Suppl l):25–34Google Scholar
  91. 91.
    Pfeiffer EF, Raptis S, Schröder K-E (1974) Einmalige intravenöse Gliben-clamid-Glukose-Belastung als Vorhersagetest. Dtsch med Wschr 99:1281PubMedGoogle Scholar
  92. 92.
    Pfeiffer EF, Schöff-ling K, Steigerwald H, Treser A, Otto M (1957) Das Problem des Sekundärversagens der oralen Diabetesbehandlung. Dtsch med Wschr 82:1528PubMedGoogle Scholar
  93. 93.
    Pissarek D, Panzram G, Lundershausen R, Adolph W, Senf L (1980) Ergebnisse einer Intensivierung der Therapie des neuentdeckten Maturity-onset-Diabetes. Endokrinologie 75, 1:105–115PubMedGoogle Scholar
  94. 94.
    Prince MJ, Olevsky JM (1980) Direct in vitro effects of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest 66:608PubMedGoogle Scholar
  95. 95.
    Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F (1977) Glukosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften 64:536PubMedGoogle Scholar
  96. 96.
    Raptis S, Pfeiffer EF (1971) Sulfonylharnstoffe als orale Antidiabetika der 1. und 2. Generation. Therapiewoche 21:578Google Scholar
  97. 97.
    Reaven GM (1984) Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus: Which defect is primary? Diabetes Care, Vol 7 (Suppl 1): 17–24PubMedGoogle Scholar
  98. 98.
    Reitman JS, Vasquez B, Klimes I, Nagluesparan M (1984) Improvement of glucose homeostasis after exercise training in non-insulin-dependent diabetes. Diabetes Care, Vol 7, Nr. 5:434–441PubMedGoogle Scholar
  99. 99.
    Rendell M (1983) C-Peptide levels as a criterion in treatment of maturity-onset-diabetes. J Clin Endocrinol Metab 57:1198–1206PubMedGoogle Scholar
  100. 100.
    Riddle CM (1985) New tactics for type II diabetes: Regimens based on intermediate-acting insulin taken at bedtime. Lancet 1:192–195PubMedGoogle Scholar
  101. 101.
    Rosak C, Schwarz O, Althoff P-H, Schöffling K, Schmidt FM (1985) Kombinierte Behandlung von Typ-II Diabetes mit Insulin und Glibenclamid nach Tablettensekundärversagen. DMW 110:1975–1980Google Scholar
  102. 102.
    Rupp WM, Barbosa JJ, Blackshear PJ, McCarthy HB, Rolde TD, Goldenberg FJ, Rubstein TG, Dorman FD, Buchwald H (1982) The use of an implantable insulin pump in the treatment of type II diabetes. New Engl J Med 307, 5:265–270PubMedGoogle Scholar
  103. 103.
    Sachse G, Willms B (1979) Klinische Bedeutung der Serumbestimmung. Diagnose und Prognose bei drohendem Sekundärversagen der Sulfonylharnstofftherapie. Med Klinik 74:1635–1640Google Scholar
  104. 104.
    Sachse G, Maser E, Federlin K (1984) Kombinationstherapie mit Insulin und Sulfonylharnstoffen bei Sekundärversagen der Sulfonylharnstofftherapie? Dtsch med Wschr 109:419PubMedGoogle Scholar
  105. 105.
    Sauer H (1985) Therapeutisches Vorgehen bei Sulfonylharnstoff-Sekundärversagen. Dtsch Med Wschr 110:27–30PubMedGoogle Scholar
  106. 106.
    Scarlett JA, Gray RS, Griffin J, Olevsky JM, Kolterman OG (1982) Insulin treatment reverse the insulin resistance of type II diabetes melitus. Diabetes Care, Vol 5, Nr 4:353–363PubMedGoogle Scholar
  107. 107.
    Simonsen D, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, De Fronzo R (1984) Mechanism of improvement in glucose metabolism after chronic Glibenclamide therapy. Diabetes, Vol 33:838–844Google Scholar
  108. 108.
    Skyler JS (1984) Non-insulin-dependent diabetes mellitus: A clinical strategy. Diabetes Care 7 (Suppl 1): 118–129PubMedGoogle Scholar
  109. 109.
    Sönksen PH, Lowy C, Perkins JR, Lim HS (1984) Non-insulin-dependent diabetes: 10 year outcome in relation to initial response to diet and subsequent sulfonylurea therapy Diabetes Care, Vol 7 (Suppl 1): 59–66PubMedGoogle Scholar
  110. 110.
    Spaethe R, Otto H (1973) Veränderungen des Blutglukose und des Seruminsulins nach Verabfolgung verschiedener kohlenhydrathaltiger Nahrungsmittel. In: Jahnke K, Mehnert H (Hrsg) Metabolische und klinische Aspekte der Kohlenhydrate in der Ernährung. Kirchheim und G, Mainz, S 74Google Scholar
  111. 111.
    Schade DS, Eaton RP, Mitchell W, Ortega Th (1980) Glucose and insulin response to high carbohydrate meals in normal and maturity-onset diabetes subjects. Diabetes Care 3:242–244PubMedGoogle Scholar
  112. 112.
    Schmidt FH (1983) Beeinflussen Sulfonylharnstoffe eine durch exogenes Insulin bewirkte Hemmung der Insulinsekretion? Vortragsmanuskript Insel Workshop, Homburg/SaarGoogle Scholar
  113. 113.
    Schneider SH, Amorosa LF, Khachadurian AK, Ruderman NB (1984) Studies on the mechanism of improved glucose control during regular exercise in type II (non-insulin-dependent) diabetes. Diabetologia 26:355–360PubMedGoogle Scholar
  114. 114.
    Schöffling K, Mehnert H, Haupt E (1984) Behandlung mit Sulfonylharnstoffen. In: Mehnert H, Schöffling K (Hrsg) Diabetologie in Klinik und Praxis. Georg Thieme, Stuttgart New YorkGoogle Scholar
  115. 115.
    Schöffling K, Orale Diabetes-Therapie 1980. Aktuel Endokrinol 1:3Google Scholar
  116. 116.
    Schöffling K, Pfeiffer EF, Ditschuneit H, Federlin K, Wildberger H (1961) 5 Jahre Sulfonylharnstofftherapie des Diabetes mellitus. Med welt (Stuttgart) 16:827Google Scholar
  117. 117.
    Schwarz O, Rosak C, Althof TP-H, Schöffling K, v. Dahl K, Schmidt FH (1984) Doppelblinde, kontrollierte Cross-over-Studie zur Behandlung von Typ-II-Diabetikern mit Insulin und Glibenclamid. Akt Endokrin 5:122Google Scholar
  118. 118.
    Stout RW (1982) Hyperinsulinaemia as an independent risk factor for atherosclerosis. Int J Obesity 6 (Suppl 1): 111–116Google Scholar
  119. 119.
    Stratmann FW (1957) Über Spätversager bei der peroralen Diabetes-Therapie und bei kombinierter Behandlung. Med Klin 52:589Google Scholar
  120. 120.
    Strauzenberg SE, Haller H, Meyer H (1958) Beitrag zum Problem der Versagerfalle bei der peroralen Diabetestherapie. Münch med Wschr 100:1535PubMedGoogle Scholar
  121. 121.
    Streja D, Boyko E, Rabkin SW (1981) Nutrition therapy in non-insulin-dependent diabetes mellitus. Diabetes Care 4:81–84PubMedGoogle Scholar
  122. 122.
    Toeller M, Gries FA, Grünklee D, Koschinsky Th (1980) Diät: Basis der Diabetestherapie trotz wechselnder Empfehlungen. Therapiewoche 30:8369Google Scholar
  123. 123.
    Traumann KJ, Hösl W, Grom E, Wittemann G (1982) Kombination von Insulin und Sulfonylharnstoffen bei der Therapie des Diabetes mellitus vom Erwachsenen-Typ. Dtsch Med Wschr 107:180–184PubMedGoogle Scholar
  124. 124.
    Trovati M, Carta Qu, Cavalot F, Vitali S, Banandi C, Lucchina PG, Focchi F, Emanuelli G, Lenti G (1984) Influence of Physical Training on Blood Glucose Control, Glucose Tolerance, Insulin Secretion, and Insulin Action in Non-Insulin-dependent Diabetes Patients. Diabetes Care 7:416–420PubMedGoogle Scholar
  125. 125.
    Turner RC, McCarthy ST, Holmann RR, Harris E (1976) Betacell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1:1252–1254PubMedGoogle Scholar
  126. 126.
    UK Prospective Study of Therapies of Maturity-Onset Diabetes (1983) 1. Effect of Diet, Sulphonylurea, Insulin or Bigua-nide Therapy of Fasting Plasma Glucose and Body Weight over one Year (a multicentre Study). Diabetologia 24:40–411Google Scholar
  127. 127.
    UK Prospective Diabetes Study (1985) II. Reduction in HbA 1C with basal Insulin Supplement, Sulphonylurea or Biguanide Therapy in Maturity-Onset Diabetes. Diabetes Care 34:793–798Google Scholar
  128. 128.
    Unger RH, Grundy (1985) Hyperglycemia as an inducer as well as a consequence of impaired isletcell function and insulin resistance: implications for the management of diabetes. Diabetologia 193:119–121Google Scholar
  129. 129.
    Vessby B, Boberg M, Karlström B, Lithell H, Werner I (1984) Improved metabolic control after supplemented fasting in overweight type II diabetic patients. Acta Med Scand 216:67–74PubMedGoogle Scholar
  130. 130.
    Vigneri R, Gullo D, Pezzino V (1984) Metformin and Insulin Receptors. Diabetes Care 7:113PubMedGoogle Scholar
  131. 131.
    Vigneri R, Pezzino V, Wong KY, Goldfìne ID (1982) Comarison of the in vitro effect of biguanides and sulfonylureides on insulin binding to its receptors in target cells. J Clin Endocrin Metab 54:95–100Google Scholar
  132. 132.
    Waldhäusl W, Ver-happer H, Bratusch-Marrain P Unterschiedliche Suppression der endogenen Insulinsekretion durch biosynthetisches Humaninsulin beim Menschen. 1. Internationales Symposium „Neue Insuline“, Freiburg/BreisgauGoogle Scholar
  133. 133.
    Wales JK (1982) Treatment of type 2 (non-insulin dependent) diabetics with diet alone. Diabetologia 23:240–245PubMedGoogle Scholar
  134. 134.
    Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7, 5:491–502PubMedGoogle Scholar
  135. 135.
    Welborn TA, Garcia-Webb P, Bonser AM (1981) Basal C-Peptide in the discrimination of type I diabetes from type II diabetes. Diabetes Care 4:616–619Google Scholar
  136. 136.
    Wilson RM, Van der Minne, Deverill I, Heller SR, Gelsthrop K, Reeves WG, Tattersell RB (1985) Insulin dependence: problems with the classification of 100 consecutive patients. Diabetic Med 2:167–172PubMedGoogle Scholar
  137. 137.
    Wilson EA, Hadden DR, Merrett JD, Montgomery DA, Weaver JA (1980) Dietary management of maturity-onset diabetes. Br Med J 280:1367PubMedGoogle Scholar
  138. 138.
    WHO (1980) Expert Committee on Diabetes mellitus. Second report. Technical Report Series 646. World Health Organization, GenevaGoogle Scholar
  139. 139.
    Zilker Th, Krönzlin Th, Schweigart U, Ermler R, Bottermann P (1976) Radioimmunologische Serumbestimmung beim manifesten Diabetes mellitus als Parameter der Therapieplanung. Med Klinik 71:761Google Scholar

Copyright information

© J. F. Bergmann Verlag, München 1986

Authors and Affiliations

  • P.-H. Althoff
    • 1
  • C. Rosak
    • 1
  1. 1.Abteilung für Endokrinologie des Zentrums der Inneren MedizinUniversitätsklinikum Frankfurt a. MDeutschland

Personalised recommendations